A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs HSK 44459 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
- 16 Jan 2025 New trial record